ABSTRACT
Mumps virus (MuV) is postulated to adhere to the "rule of six" for efficient replication. To examine the requirement for MuV, minigenomes of nonpolyhexameric length (6n-1 and 6n+1) were analyzed. Expression of the reporter gene CAT was significantly reduced with minigenomes of nonpolyhexameric length compared to the wild type 6n genome, and reduction was more pronounced for the 6n-1 than for the 6n+1 minigenome. That 6n-1 genomes are impacted by nonconformance with the rule of six to a greater degree as compared to 6n+1 genomes was also suggested with MuV derived from cDNA coding for 6n+1 or 6n-1 genomes. While viruses recovered from 6n+1 cDNAs maintained a nonpolyhexameric genome length over multiple replication cycles, viruses rescued from the 6n-1 cDNAs acquired length correcting mutations rapidly following rescue. Our data indicate that polyhexameric genomes are the preferred template for the MuV RNA polymerase, but that this requirement is not absolute.
Subject(s)
Genome, Viral , Mumps virus/physiology , Virus Replication/genetics , Animals , Cell Line , Chlorocebus aethiops , DNA, Complementary , DNA, Viral , DNA-Directed RNA Polymerases/metabolism , Genome Size , Mumps virus/genetics , Vero Cells , Viral Proteins/metabolismABSTRACT
As a member of the family paramyxoviridae, subfamily paramyxovirinae, the genome of mumps virus (MuV) is postulated to be polyhexameric in length in order to be able to replicate efficiently. While all natural MuV strains sequenced so far obey to this "rule of six," we describe here the isolation of recombinant MuVs that appeared to contain an additional U residue in the homopolymeric tract of the F gene-end signal, resulting in a genome length of 6n + 1. Sequencing of several plaque-purified viruses from these preparations did not reveal the existence of length-correcting mutations, suggesting that they are violators of the rule of six. Employing high-throughput sequencing technology, we provide evidence that the insertion of an additional U residue is mainly the result of the rescue system used that relies on T7 RNA polymerase. Limited in vitro and in vivo testing of the viruses did not reveal any significant impact of the longer genome on virus replication or virulence, suggesting that the rule of six is not a strict requirement for MuV replication.
Subject(s)
Mumps virus/physiology , Mutagenesis, Insertional , Mutant Proteins/metabolism , Viral Fusion Proteins/metabolism , Virus Replication , Animals , Chlorocebus aethiops , Mumps virus/genetics , Mumps virus/isolation & purification , Mutant Proteins/genetics , RNA, Viral/genetics , Sequence Analysis, DNA , Vero Cells , Viral Fusion Proteins/genetics , Viral Plaque Assay , VirulenceABSTRACT
Recently, numerous large-scale mumps outbreaks have occurred in vaccinated populations. Clinical isolates sequenced from these outbreaks have invariably been of genotypes distinct from those of vaccine viruses, raising concern that certain mumps virus strains may escape vaccine-induced immunity. To investigate this concern, sera obtained from children 6 weeks after receipt of measles, mumps, and rubella (MMR) vaccine were tested for the ability to neutralize a carefully selected group of genetically diverse mumps virus strains. Although the geometric mean neutralizing antibody titer of the sera was lower against some virus strains than others, all viruses were readily neutralized, arguing against immune escape.
Subject(s)
Disease Outbreaks , Measles-Mumps-Rubella Vaccine/immunology , Mumps virus/immunology , Mumps/epidemiology , Mumps/immunology , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Child , Child, Preschool , Female , Humans , Male , Measles-Mumps-Rubella Vaccine/administration & dosage , Molecular Sequence Data , Mumps/virology , Mumps virus/classification , Mumps virus/genetics , Phylogeny , United States/epidemiology , VaccinationABSTRACT
Mumps virus (MuV) is highly neurotropic and was the leading cause of aseptic meningitis in the Western Hemisphere prior to widespread use of live attenuated MuV vaccines. Due to the absence of markers of virus neuroattenuation and neurovirulence, ensuring mumps vaccine safety has proven problematic, as demonstrated by the occurrence of aseptic meningitis in recipients of certain vaccine strains. Here we examined the genetic basis of MuV neuroattenuation and neurovirulence by generating a series of recombinant viruses consisting of combinations of genes derived from a cDNA clone of the neurovirulent wild-type 88-1961 strain (r88) and from a cDNA clone of the highly attenuated Jeryl Lynn vaccine strain (rJL). Testing of these viruses in rats demonstrated the ability of several individual rJL genes and gene combinations to significantly neuroattenuate r88, with the greatest effect imparted by the rJL nucleoprotein/matrix protein combination. Interestingly, no tested combination of r88 genes, including the nucleoprotein/matrix protein combination, was able to convert rJL into a highly neurovirulent virus, highlighting mechanistic differences between processes involved in neuroattenuation and neurovirulence.
Subject(s)
Attention , Central Nervous System/virology , Genes, Viral , Mumps virus/pathogenicity , Animals , Chlorocebus aethiops , Mumps virus/genetics , Mumps virus/physiology , Rats , Rats, Inbred Lew , Reverse Transcriptase Polymerase Chain Reaction , Vero Cells , Virulence , Virus ReplicationABSTRACT
Post-vaccinal encephalitis, although relatively uncommon, is a known adverse event associated with many live, attenuated smallpox vaccines. Although smallpox vaccination ceased globally in 1980, vaccine manufacture has resumed in response to concerns over the possible use of smallpox virus as an agent of bioterrorism. To better support the production of safer smallpox vaccines, we previously reported the development of a mouse model in which a relatively attenuated vaccine strain (Dryvax) could be discerned from a more virulent laboratory strain (WR). Here we have further tested the performance of this assay by evaluating the neurovirulence of several vaccinia virus-based smallpox vaccines spanning a known range in neurovirulence for humans. Our data indicate that testing of 10-100 pfu of virus in mice following intracranial inoculation reliably assesses the virus's neurovirulence potential for humans.
Subject(s)
Encephalomyelitis, Acute Disseminated/diagnosis , Mice , Models, Animal , Smallpox Vaccine/adverse effects , Smallpox Vaccine/therapeutic use , Vaccinia virus/immunology , Animals , Animals, Newborn , Brain/pathology , Brain/virology , Cells, Cultured , Chick Embryo , Chlorocebus aethiops , Drug Evaluation, Preclinical , Encephalomyelitis, Acute Disseminated/etiology , Encephalomyelitis, Acute Disseminated/mortality , Encephalomyelitis, Acute Disseminated/pathology , Time Factors , Vaccinia/complications , Vaccinia/mortality , Vaccinia/pathology , Vaccinia/virology , Vero Cells , Virulence , Virus Replication/physiologyABSTRACT
The recent global resurgence of mumps has drawn attention to the continued need for robust mumps immunization programs. Unfortunately, some vaccines derived from inadequately attenuated vaccine strains of mumps virus have caused meningitis in vaccinees, leading to withdrawal of certain vaccine strains from the market, public resistance to vaccination, or in some cases, cessation of national mumps vaccination programs. The most widely implicated mumps vaccine in cases of postvaccination meningitis is derived from the Urabe AM9 strain, which remains in use in some countries. The Urabe AM9 vaccine virus has been shown to exhibit a considerable degree of nucleotide and amino acid heterogeneity. Some studies have specifically implicated variants containing a lysine residue at amino acid position 335 in the hemagglutinin-neuraminidase (HN) protein with neurotoxicity, whereas a glutamic acid residue at this position was associated with attenuation. To test this hypothesis we generated two modified Urabe AM9 cDNA clones coding either for a lysine or a glutamic acid at position 335 in the HN gene. The two viruses were rescued by reverse genetics and characterized in vitro and in vivo. Both viruses exhibited similar growth kinetics in neuronal and non-neuronal cell lines and were of similar neurotoxicity when tested in rats, suggesting that amino acid 335 is not a crucial determinant of Urabe AM9 growth or neurovirulence.
Subject(s)
Amino Acid Substitution , HN Protein/genetics , Mumps Vaccine/genetics , Mumps virus/genetics , Animals , Chlorocebus aethiops , DNA, Complementary/genetics , Humans , Lysine/genetics , Mumps virus/pathogenicity , Mumps virus/physiology , Mutation , RNA, Viral/genetics , Rats , Rats, Inbred Lew , Sequence Analysis, DNA , Vaccines, Attenuated/genetics , Vero Cells , Virulence , Virus ReplicationABSTRACT
Although several effective mumps virus vaccines have been developed, almost nothing is known about the genetic changes responsible for loss of virulence. One vaccine, Urabe AM9, was withdrawn from the market because of insufficient attenuation. The vaccine was found to contain a mixture of viruses that could be distinguished based on the sequence of the hemagglutinin-neuraminidase gene (HN). Viruses containing lysine at HN amino acid position 335 were isolated from cases of post-vaccination parotitis or meningitis whereas viruses containing glutamic acid at this position were not associated with post-vaccination disease. Using a rat based model of mumps neurovirulence, we demonstrate that this latter virus is significantly attenuated compared to a virus isolated from a patient with post-vaccination meningitis. Complete sequence analysis of the genomes of the two viruses identified sixteen genetic differences, some or all of which must be responsible for differences in virulence. These same genetic differences also account for changes in tropism in cell culture.
Subject(s)
HN Protein/genetics , Mumps virus/genetics , Mumps virus/pathogenicity , Mutation, Missense , Amino Acid Substitution/genetics , Animals , Humans , Meningitis, Viral/virology , Mumps Vaccine/adverse effects , Mumps virus/isolation & purification , Parotitis/virology , Rats , Sequence Analysis, DNA , Vaccines, Attenuated/adverse effects , VirulenceABSTRACT
Recent mumps outbreaks in older vaccinated populations were caused primarily by genotype G viruses, which are phylogenetically distinct from the genotype A vaccine strains used in the countries affected by the outbreaks. This finding suggests that genotype A vaccine strains could have reduced efficacy against heterologous mumps viruses. The remote history of vaccination also suggests that waning immunity could have contributed to susceptibility. To examine these issues, we obtained consecutive serum samples from children at different intervals after vaccination and assayed the ability of these samples to neutralize the genotype A Jeryl Lynn mumps virus vaccine strain and a genotype G wild-type virus obtained during the mumps outbreak that occurred in the United States in 2006. Although the geometric mean neutralizing antibody titers against the genotype G virus were approximately one-half the titers measured against the vaccine strain, and although titers to both viruses decreased with time after vaccination, antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralized the outbreak-associated virus at all time points tested.
Subject(s)
Antibodies, Viral/immunology , Mumps Vaccine/administration & dosage , Mumps Vaccine/immunology , Mumps virus/immunology , Mumps/virology , Antibody Formation , Child , Child, Preschool , Disease Outbreaks/prevention & control , Humans , Immunization , Measles-Mumps-Rubella Vaccine/administration & dosage , Measles-Mumps-Rubella Vaccine/immunology , Measles-Mumps-Rubella Vaccine/standards , Mumps/epidemiology , Mumps/immunology , Mumps Vaccine/standards , Mumps virus/classification , Neutralization Tests , Treatment Outcome , Vaccines, Combined/immunology , Vaccines, Combined/standardsABSTRACT
Influenza is generally regarded as an infection of the respiratory tract; however, neurological involvement is a well-recognized, although uncommon, complication of influenza A virus infection. The authors previously described the development of a rat model for studying influenza virus infection of the central nervous system (CNS). This model was used here to study the role of virus genes in virus replication and spread in brain. In the present work, an infectious cDNA clone of the neurotoxic WSN strain of influenza virus (rWSN) was altered by site-directed mutagenesis at five loci that corresponded to changes previously shown to confer temperature sensitivity and attenuation of the A/Ann Arbor/6/60 strain (PB1Delta 391, PB1Delta 581, and PB1Delta 661; PB2Delta 265, and NPDelta 34). Whereas rWSN and its mutated derivative (mu-rWSN) replicated equally well in MDCK cells at 37 degrees C (the body temperature of rats), rWSN grew to higher titers and infection was more widespread compared to mu-rWSN in rat brain. These results demonstrate that the five mutations that confer attenuation of the A/Ann Arbor/6/60 influenza virus strain for the respiratory system also confer attenuation for the central nervous system. Further in vivo and in vitro examination of these five mutations, both individually and in combination, will likely provide important information on the role of specific virus genes in virulence and pathogenesis.
Subject(s)
Central Nervous System/virology , Genes, Viral , Influenza A virus/genetics , Viral Proteins/genetics , Virulence/genetics , Virus Replication , Animals , Influenza A virus/physiology , Mutagenesis, Site-Directed , Orthomyxoviridae Infections/immunology , Rats , Temperature , Viral Proteins/biosynthesis , Viral Proteins/immunologyABSTRACT
Wild-type mumps viruses (MuVs) are highly neurotropic and, prior to widespread vaccination programmes, were a major cause of viral meningitis and encephalitis in most developed countries. At present, there are no markers for virus attenuation, apart from the failure of a passaged isolate to produce clinical symptoms in vaccinees. Indeed, some MuV vaccines have retained residual neurovirulence properties and have caused aseptic meningitis in vaccinees. Three amino acid changes associated with the neuroattenuation of a wild-type MuV strain were identified previously. This study evaluated the impact of these changes on the function of the respective proteins. The data demonstrated that the Ser-->Asp amino acid substitution at position 466 in the haemagglutinin-neuraminidase protein resulted in decreased receptor binding and neuraminidase activity, the Ala/Thr-->Thr selection in the fusion protein resulted in decreased fusion activity, and the Ile-->Val substitution in the polymerase resulted in increased replicative/transcriptional activity. These data suggest a polygenic component (i.e. specific and inter-related roles of these amino acid changes) to MuV neuroattenuation.
Subject(s)
DNA-Directed DNA Polymerase/genetics , DNA-Directed RNA Polymerases/genetics , HN Protein/genetics , Mumps virus/genetics , Mutation , Viral Fusion Proteins/genetics , Viral Proteins/genetics , Animals , Cell Line , Chick Embryo , DNA Primers , Gene Fusion , HeLa Cells , Humans , Kinetics , Mumps virus/enzymology , Neuraminidase/genetics , Polymerase Chain Reaction , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , ThreonineABSTRACT
Neonatal Borna disease virus (BDV) infection of the rat brain is associated with microglial activation and damage to the certain neuronal populations. Since persistent BDV infection of neurons in vitro is noncytolytic and noncytopathic, activated microglia have been suggested to be responsible for neuronal cell death in vivo. However, the mechanisms of activation of microglia in neonatally BDV-infected rat brain have not been investigated. To address these issues, activation of primary rat microglial cells was studied following exposure to purified BDV or to persistently BDV-infected primary cortical neurons or after BDV infection of primary mixed neuron-glial cultures. Neither purified virus nor BDV-infected neurons alone activated primary microglia as assessed by the changes in cell shape or production of the proinflammatory cytokines. In contrast, in the BDV-infected primary mixed cultures, we observed proliferation of microglia cells that acquired the round morphology and expressed major histocompatibility complex molecules of classes I and II. These manifestations of microglia activation were observed in the absence of direct BDV infection of microglia or overt neuronal toxicity. In addition, compared to uninfected mixed cultures, activation of microglia in BDV-infected mixed cultures was associated with a significantly greater lipopolysaccharide-induced release of tumor necrosis factor alpha, interleukin 1beta, and interleukin 10. Taken together, the present data are the first in vitro evidence that persistent BDV infection of neurons and astrocytes rather than direct exposure to the virus or dying neurons is critical for activating microglia.
Subject(s)
Borna Disease/physiopathology , Borna disease virus , Microglia/physiology , Microglia/virology , Animals , Cells, Cultured , Cytotoxicity Tests, Immunologic , Histocompatibility Antigens/metabolism , Immunohistochemistry , In Vitro Techniques , Interleukin-10/metabolism , Interleukin-1beta/metabolism , Microglia/cytology , Microglia/metabolism , Rats , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Mumps virus is a highly neurotropic virus with evidence of central nervous system invasion (CNS) in approximately half of all cases of infection. In countries where live attenuated mumps virus vaccines were introduced, the number of mumps cases declined dramatically; however, recently, the safety of some vaccine strains has been questioned. For example, one of the most widely used vaccines, the Urabe AM9 strain, was causally associated with meningitis, leading to the withdrawal of this product from the market in several countries. This highlights the need for a better understanding of the attenuation process and the identification of markers of attenuation. To this end, we further attenuated the Urabe AM9 strain by serial passage in cell culture and compared the complete nucleotide sequences of the parental and passaged viruses. Interestingly, despite a dramatic decrease in virus virulence (as assayed in rats), the only genomic changes were in the form of changes in the level of genetic heterogeneity at specific genome sites, i.e., either selection of one nucleotide variant at positions where the starting material exhibited nucleotide heterogeneity or the evolution of an additional nucleotide to create a heterogenic site. This finding suggests that changes in the level of genetic heterogeneity at specific genome sites can have profound neurovirulence phenotypic consequences and, therefore, caution should be exercised when evaluating genetic markers of virulence or attenuation based only on a consensus sequence.
Subject(s)
Mumps virus/genetics , Mumps virus/pathogenicity , Animals , Animals, Newborn , Central Nervous System Infections/virology , Chickens , Chlorocebus aethiops , Fibroblasts , Genome, Viral , Mumps/virology , Mumps Vaccine , Mumps virus/classification , Mumps virus/metabolism , Phenotype , RNA, Viral/metabolism , Rats , Rats, Inbred Lew , Vero Cells , VirulenceABSTRACT
Because of the highly neurotropic and neurovirulent properties of wild-type mumps viruses, most national regulatory organizations require neurovirulence testing of virus seeds used in the production of mumps vaccines. Such testing has historically been performed in monkeys; however, some data suggest that testing in monkeys does not necessarily discriminate among the relative neurovirulent risks of mumps virus strains. To address this problem, a collaborative study was initiated by the National Institute for Biological Standards and Control in the United Kingdom and the Food and Drug Administration in the United States, to test a novel rat-based mumps virus neurovirulence safety test. Results indicate that the assay correctly assesses the neurovirulence potential of mumps viruses in humans and is robust and reproducible.
Subject(s)
Brain/virology , Mumps Vaccine/adverse effects , Mumps virus/pathogenicity , Virology/methods , Virulence , Animals , Brain/pathology , Humans , Rats , Reproducibility of ResultsABSTRACT
The only US FDA licensed smallpox vaccine, Dryvax, was associated with rare but serious neurological adverse events. After smallpox was eradicated in the United States, mass vaccination ceased in 1971. As counter-bioterrorism/biowarfare measures, new smallpox vaccines are now being investigated. However, there are no established pre-clinical neurotoxicity assays with which to evaluate these new vaccines prior to licensure. Here we report the development and initial characterization of a small animal neurotoxicity assay for vaccinia-based smallpox vaccines using Dryvax virus as a reference vaccine strain and the neuroadapted Western Reserve (WR) strain as a neurotoxic positive control. In neonatally inoculated mice, the WR strain produced significantly greater and more rapid onset of mortality than the Dryvax vaccine reference. Expression of virus antigen in neural cells and infectious virus replication in the brain was also significantly different between the two strains. In addition, the appearance of high titer virus antibody correlated with the clearance of virus from brain. With further validation, this assay incorporating a licensed vaccine reference standard and positive control strain may provide important pre-clinical neurotoxicity data on new vaccinia-based smallpox vaccine strains.
Subject(s)
Nervous System Diseases/etiology , Nervous System Diseases/pathology , Smallpox Vaccine/adverse effects , Vaccinia virus/immunology , Vaccinia/pathology , Animals , Animals, Newborn , Antibodies, Viral/analysis , Antibodies, Viral/biosynthesis , Antigens, Viral/immunology , Brain/pathology , Brain/virology , Brain Chemistry/physiology , Fluorescent Antibody Technique, Indirect , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Mice , Myelin Sheath/pathology , Nervous System Diseases/virology , Neurons/pathology , Smallpox Vaccine/immunology , Survival Analysis , Vaccinia/complications , Vaccinia/virology , Viral Plaque Assay , Virus ReplicationABSTRACT
Mumps virus is highly neurotropic and, prior to widespread vaccination programs, was the major cause of viral meningitis in the United States. Nonetheless, the genetic basis of mumps virus neurotropism and neurovirulence was until recently not understood, largely due to the lack of an animal model. Here, nonneurovirulent (Jeryl Lynn vaccine) and highly neurovirulent (88-1961 wild type) mumps virus strains were passaged in human neural cells or in chicken fibroblast cells with the goal of neuroadapting or neuroattenuating the viruses, respectively. When tested in our rat neurovirulence assay against the respective parental strains, a Jeryl Lynn virus variant with an enhanced propensity for replication (neurotropism) and damage (neurovirulence) in the brain and an 88-1961 wild-type virus variant with decreased neurotropic and neurovirulent properties were recovered. To determine the molecular basis for the observed differences in neurovirulence and neuroattenuation, the complete genomes of the parental strains and their variants were fully sequenced. A comparison at the nucleotide level associated three amino acid changes with enhanced neurovirulence of the neuroadapted vaccine strain: one each in the nucleoprotein, matrix protein, and polymerase and three amino acid changes with reduced neurovirulence of the neuroattenuated wild-type strain: one each in the fusion protein, hemagglutinin-neuraminidase protein, and polymerase. The potential role of these amino acid changes in neurotropism, neurovirulence, and neuroattenuation is discussed.
Subject(s)
Amino Acid Sequence , Brain/pathology , Central Nervous System Viral Diseases/physiopathology , Genetic Variation , Mumps virus/genetics , Mumps virus/pathogenicity , Animals , Brain/virology , Cell Line , Central Nervous System Viral Diseases/pathology , Central Nervous System Viral Diseases/virology , Chlorocebus aethiops , Cytopathogenic Effect, Viral , Disease Models, Animal , Humans , Mumps/pathology , Mumps/physiopathology , Mumps/virology , Mumps Vaccine , Neurons/pathology , Neurons/virology , Phenotype , Rats , Rats, Inbred Lew , Vaccines, Attenuated , Vero Cells , Virulence/genetics , Virus ReplicationABSTRACT
Cerebellar pathology has been associated with a number of developmental behavioral disorders, including autism spectrum disorders. Despite the fact that perinatal virus infections have been implicated in neurodevelopmental damage, few animal models have been developed to study the pathogenesis involved. One of the most interesting in vivo models of virus-induced cerebellar damage is the neonatal Borna disease virus (BDV) infection of the rat brain. The present review describes molecular, cellular, neuroanatomical, neurochemical and behavioral features of the BDV model and also provides a basis for a new understanding of the pathogenic mechanisms of cerebellar malformation and associated behavioral deficits.
Subject(s)
Borna Disease/physiopathology , Cerebellum/physiopathology , Animals , Animals, Newborn , Borna Disease/genetics , Borna disease virus , Cerebellum/virology , Disease Models, Animal , Humans , Infant, NewbornABSTRACT
While intrathymic MHC expression influences the specificity of developing thymocytes, we considered that peripheral MHC expression might influence the reactivity of postthymic T cells. We now report for CD4(+) T cells that peripheral MHC-II expression does influence their reactivity and self-tolerance. Upon transfer into MHC-II-deficient lymphopenic hosts, mature CD4(+) T cells were found to acquire an activated memory phenotype and to become: (1) autoreactive against syngeneic MHC-II(+) skin grafts, (2) hyperreactive against third-party MHC-II(+) skin grafts, and (3) functionally dysregulated, resulting in a lymphoproliferative disorder characterized by intraepithelial infiltrations. Peripheral MHC-II expression appeared to influence CD4(+) T cell reactivity by two complementary mechanisms: maintenance of CD4(+)CD25(+) regulatory T cells ("suppression") and direct dampening of CD4(+) T cell reactivity ("tuning").
Subject(s)
Autoantigens/metabolism , CD4-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class II/metabolism , Self Tolerance , Adoptive Transfer , Animals , Autoimmunity , Immunologic Memory , Lymphocyte Activation , Lymphopenia/immunology , Lymphoproliferative Disorders/etiology , Lymphoproliferative Disorders/immunology , Lymphoproliferative Disorders/pathology , Mice , Mice, Knockout , Models, Immunological , Skin Transplantation/immunology , Skin Transplantation/pathology , T-Lymphocytes/immunology , Transplantation, IsogeneicABSTRACT
Borna disease virus (BDV) infection produces a variety of clinical diseases, from behavioral illnesses to classical fatal encephalitis (i.e., Borna disease [BD]). Since the genomes of most BDV isolates differ by less than 5%, host factors are believed responsible for much of the reported variability in disease expression. The contribution of BDV genomic differences to variation in BD expression is largely unexplored. Here we compared the clinical outcomes of rats infected with one of two related BDV variants, CRP3 or CRNP5. Compared to rats inoculated with CRP3, adult and newborn Lewis rats inoculated with CRNP5 had more severe and rapidly fatal neurological disease, with increased damage to the hippocampal pyramidal neurons and rapid infection of brain stem neurons. To identify possible virus-specific contributions to the observed variability in disease outcome, the genomes of CRP3 and CRNP5 were sequenced. Compared to CRP3, there were four nucleotide changes in the CRNP5 variant, two each in the G protein and in the L polymerase, resulting in four amino acid changes. These results suggest that small numbers of genomic differences between BDV variants in the G protein and/or L polymerase can contribute to the variability in BD outcomes.
Subject(s)
Borna disease virus/pathogenicity , Brain/pathology , Genetic Variation , Glycoproteins/genetics , RNA-Dependent RNA Polymerase/genetics , Viral Proteins/genetics , Animals , Animals, Newborn , Antibodies, Viral/blood , Base Sequence , Borna Disease/pathology , Borna Disease/physiopathology , Borna Disease/virology , Borna disease virus/chemistry , Borna disease virus/genetics , Brain/virology , Glycoproteins/chemistry , Glycoproteins/metabolism , Molecular Sequence Data , RNA-Dependent RNA Polymerase/chemistry , RNA-Dependent RNA Polymerase/metabolism , Rats , Rats, Inbred Lew , Viral Proteins/chemistry , Viral Proteins/metabolism , Virulence , Virus ReplicationABSTRACT
The pathogenic mechanisms of gene-environment interactions determining variability of human neurodevelopmental disorders remain unclear. In the two consecutive papers, we used the neonatal Borna disease virus (BDV) infection rat model of neurodevelopmental damage to evaluate brain pathology, monoamine alterations, behavioral deficits, and responses to pharmacological treatments in two inbred rat strains, Lewis and Fisher344. The first paper reports that despite comparable virus replication and distribution in the brain of both rat strains, neonatal BDV infection produced significantly greater thinning of the neocortex in BDV-infected Fisher344 rats compared to BDV-infected Lewis rats, while no strain-related differences were found in BDV-induced granule cell loss in the dentate gyrus of the hippocampus and cerebellar hypoplasia. Unlike BDV-infected Lewis rats, more severe BDV-induced brain pathology in Fisher344 rats was associated with (1) greater locomotor activity to novelty and (2) impairment of habituation and prepulse inhibition of the acoustic startle response. The present data demonstrate that the same environmental insult can produce differential neuroanatomical and behavioral abnormalities in genetically different inbred rat strains.
Subject(s)
Borna Disease/genetics , Brain/virology , Genetic Predisposition to Disease/genetics , Nerve Degeneration/genetics , Neurons/virology , Acoustic Stimulation , Animals , Animals, Newborn , Body Weight/genetics , Borna Disease/virology , Brain/pathology , Brain/physiopathology , Disease Models, Animal , Female , Genotype , Habituation, Psychophysiologic/genetics , Nerve Degeneration/physiopathology , Nerve Degeneration/virology , Neural Inhibition/genetics , Neurons/pathology , Pregnancy , Psychomotor Agitation/genetics , Psychomotor Agitation/physiopathology , Psychomotor Agitation/virology , Rats , Rats, Inbred F344 , Rats, Inbred Lew , Reflex, Startle/genetics , Viral LoadABSTRACT
The gene-environment interplay is thought to determine variability in clinical conditions and responses to therapy in human neurodevelopmental disorders. Studying abnormal brain and behavior development in inbred strains of rodents can help in the identification of the complex pathogenic mechanisms of the host-environment interaction. This paper is the second one in a series of the two reports of the use of the Borna disease virus (BDV) infection model of neurodevelopmental damage to characterize effects of genetic background on virus-induced neurodevelopmental damage in inbred rat strains, Lewis and Fisher344. The present data demonstrate that neonatal BDV infection produced regional and strain-related alterations in levels of serotonin, norepinephrine and in levels of serotonin turnover at postnatal day 120. Neonatal BDV infection also induced upregulation of hippocampal 5-HT(1a) and cortical 5-HT(2a) receptors in Lewis rats and downregulation of cortical 5-HT(2a) receptors in Fisher344 rats. BDV-associated regional downregulation of D(2) receptors and dopamine transporter sites were noted in Fisher344 rats. In addition to the neurochemical disturbances, neonatal BDV infection induced differential responses to serotonin compounds. While 8-OH-DPAT suppressed virus-enhanced ambulation in BDV-infected Fisher344, fluoxetine inhibited virus-induced hyperactivity in BDV-infected Lewis rats only. The present data provide new insights into the pathogenic events that lead to differential responses to pharmacological treatments in genetically different animals following exposure to the same environmental challenge.